Want to join the conversation?
$BA expects 2016 EPS of $8.45-8.65 and non-GAAP EPS of $8.15-8.35. Revenue is expected to be $93-95Bil, including commercial deliveries of 740-745. Operating cash flow is expected to be about $10Bil. Research and development expenses are predicted to be about $3.6Bil and capital expenditures are seen to be about $2.8Bil.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.